Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA scheduling updates include the temporary placement of 2-Fluorodeschloroketamine in Schedule I due to its abuse potential. This regulatory action highlights challenges in controlling novel synthetic substances. Clinicians should stay informed…
Schedules of Controlled Substances: Diphenidine Schedule I Placement
The DEA has placed diphenidine into Schedule I due to its abuse potential and lack of medical use. This diphenidine schedule I placement highlights challenges in regulating novel synthetic drugs. Clinicians should screen for diphenidine use alongside…
Policy Watch: 20 Regulatory Updates — June 06, 2026
The DEA synthetic cannabinoids Schedule I June 2026 updates highlight new regulatory actions on synthetic cannabinoids with high abuse potential. These changes affect clinical research and patient safety. Clinicians should stay informed about these…
Policy Watch: 20 Regulatory Updates — June 02, 2026
The schedules of controlled substances placement June 02 2026 report covers 20 regulatory updates affecting synthetic cannabinoids and opioids. These placements impact clinical research and patient care. Clinicians should stay informed on these…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has designated synthetic cannabinoids schedule I designation for CUMYL-PEGACLONE due to its high abuse potential and no accepted medical use. This scheduling reflects ongoing regulatory efforts to control novel synthetic cannabinoids. Clinicians…
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA has placed diphenidine in Schedule I, classifying it as a controlled substance with high abuse potential. Diphenidine is a synthetic dissociative drug posing public health risks. Awareness of diphenidine schedule I status aids clinicians in…